Sort
23,748 grants matching “melanoma”
Oncogenic Met Signaling in Urologic Malignancies
$558,896Donald Bottaro · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Manipulating normal estrogen physiology as a therapeutic approach in cancer
$558,602Donald P McDonnell · Duke University · R01 · FY2023 · CA
Understanding how adrenergic signaling influences immune contexture of tumors and the efficacy of checkpoint inhibitors
$558,602Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2020 · CA
Targeting Aldehyde Dehydrogenase for Cancer Prevention
$558,440Gavin P. Robertson · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2024 · CA
Characterization and Functional Analysis of Breast Cancer Secreted Exosomes in Ma
$558,404David Charles Lyden · Weill Medical Coll Of Cornell Univ · U01 · FY2014 · CA
MYELOID-DERIVED SUPPRESSOR CELLS EXPRESSING MYELOPEROXIDASE DIRECTLY INHIBIT ADAPTIVE IMMUNE CELLS LIMITING IMMUNOTHERAPY IN MELANOMA
$558,390West Virginia University Research Corporation · · FY2019 · Defense Health Agency
Clinical production of viral vectors for cancer gene therapy
$558,354Steven Feldman · Division Of Basic Sciences - Nci · ZIC · FY2014 · CA
Non-invasive imaging of the anti-tumor immune response
$558,258Hidde L Ploegh · Boston Children'S Hospital · R01 · FY2024 · CA
NK CELLS INDUCE DCI-MEDIATED ANTI-TUMOR IMMUNITY
$558,125Pawel Kalinski · University Of Pittsburgh At Pittsburgh · P01 · FY2009 · CA
Discovery of chemical probes for uveal melanoma
$558,016Erwin G Van Meir · Emory University · R01 · FY2014 · CA
Role of Desmoglein 1 in Keratinocyte-Melanocyte Communication and Melanoma
$558,013Kathleen Janee Green · Northwestern University At Chicago · R01 · FY2024 · CA
A NEW VACCINATION STRATEGY FOR TREATMENT OF MELANOMA
$558,000Regents Of The University Of Michigan · · FY2016 · Department of Defense
Combinations of Receptor-Targeted Alpha Radionuclide Therapy and Immune Checkpoint Inhibitors for Melanoma Treatment
$557,992Yubin Miao · University Of Colorado Denver · R01 · FY2025 · CA
Nanoconjugate delivery of proliferation and checkpoint inhibitors to treat glial tumors
$557,887Julia Y Ljubimova · Cedars-Sinai Medical Center · R01 · FY2016 · CA
Development of a translational imaging tool as a predictive biomarker for anti-PD-1/PD-L1 immunotherapies
$557,734Michael John Evans · University Of California, San Francisco · R01 · FY2018 · EB
Immune Therapy for Brain Metastasis
$557,726Lucia Beatrice Jilaveanu · Yale University · R01 · FY2025 · CA
Clinical Analysis Of Disorders Of Hearing And Balance
$557,577Carmen Crowell Brewer · National Institute On Deafness And Other Communication Disorders · ZIA · FY2009 · DC
Elucidation of novel anti-angiogenic therapies for the prevention and treatment of neovascular glaucoma
$557,501Silvia V Montaner · University Of Maryland Baltimore · R01 · FY2022 · EY
Development of a translational imaging tool as a predictive biomarker for anti-PD-1/PD-L1 immunotherapies
$557,470Michael John Evans · University Of California, San Francisco · R01 · FY2021 · EB
Development of Organometallic Protein Kinase Inhibitors with Anticancer Activity
$557,335Eric Meggers · Wistar Institute · P01 · FY2009 · CA
Background free amplified single-molecule FISH for in situ and flow cytometric applications
$557,328Sanjay Tyagi · Rbhs-New Jersey Medical School · R01 · FY2020 · CA
Background free amplified single-molecule FISH for in situ and flow cytometric applications
$557,328Sanjay Tyagi · Rbhs-New Jersey Medical School · R01 · FY2021 · CA
T-cell intrinsic mechanisms of resistance to PD-1 checkpoint blockade
$557,231Michelle Krogsgaard · New York University School Of Medicine · R01 · FY2023 · CA
Molecular Mechanism of UV Protection in Cutaneous Melanoma
$557,211Chengyu Liang · University Of Southern California · R01 · FY2019 · ES
Rewiring Pathways and Networks by Environmental Perturbations
$557,204Marc Vidal · Dana-Farber Cancer Inst · R01 · FY2008 · ES